NMN vs NR vs NAD+: Which Is Best for Raising NAD? BioHarmony head-to-head comparison
Head-to-Head Comparison

NMN vs NR vs NAD+: Which Is Best for Raising NAD?

Should I take NMN, NR, or a direct NAD+ IV?

Reviewed 09/07/2026

NMN scores 6.3, NR 6.1, and direct NAD+ 5.0. The oral precursors win on evidence and price. NMN takes blood sugar and metabolic health. NR takes cardiovascular and neuroprotection. Direct NAD+ IV wins no use case here, costs several times more, and rests on one human pharmacokinetic study.

  • The route matters more than the molecule. NMN and NR are swallowed and converted. Direct NAD+ has to be infused, because the intact coenzyme degrades in the gut.
  • NMN 6.3 and NR 6.1 are a coin flip on score, so pick by endpoint: NMN for blood sugar and metabolic health, NR for vascular and neurologic targets.
  • Direct NAD+ at 5.0 has exactly one human study, and it measured pharmacokinetics, not benefit. Intact cellular uptake is still contested.
  • Price gap is the loudest fact here. NR is $40 to $50 a month, NMN $40 to $100, and a clinic NAD+ IV is an ESTIMATED $300 to $1,600.
  • Every one of the three raises NAD+ more reliably than it changes how you feel. Memory scores 1.0, 1.0 and 2.2, so no route earns that claim.

At a Glance

NMN (Nicotinamide Mononucleotide)
Option A

NMN (Nicotinamide Mononucleotide)

6.3 / 10 Worth trying
Upside
  • Efficacy 2.2
  • Breadth 2.5
  • Evidence 2.8
  • Speed 2.8
  • Durability 1.8
  • Bioindividuality 2.8
Downside
  • Safety Risk 1.5
  • Side Effects 1.5
  • Cost 3.0
  • Effort 1.2
  • Opportunity Cost 2.5
  • Dependency 1.0
  • Reversibility 1.0
Best at:
  • Metabolic Health 6.5
  • Mitochondrial 6.0
  • Longevity 5.5
  • Healthspan 5.5

Oral NAD+ precursor, one enzymatic step from NAD+. BioHarmony 6.3, worth trying.

Read full BioHarmony report →

NR (Nicotinamide Riboside)
Option B

NR (Nicotinamide Riboside)

6.1 / 10 Worth trying
Upside
  • Efficacy 2.1
  • Breadth 2.3
  • Evidence 2.6
  • Speed 3.0
  • Durability 1.4
  • Bioindividuality 2.0
Downside
  • Safety Risk 1.4
  • Side Effects 1.3
  • Cost 3.0
  • Effort 1.2
  • Opportunity Cost 2.5
  • Dependency 1.0
  • Reversibility 1.0
Best at:
  • Mitochondrial 5.5
  • Cardiovascular 5.0
  • Metabolic Health 5.0
  • Neuroprotection 5.0

Oral NAD+ precursor, converted to NMN first. BioHarmony 6.1, worth trying.

Read full BioHarmony report →

NAD+ (Direct)
Option C

NAD+ (Direct)

5.0 / 10 🤷 Neutral
Upside
  • Efficacy 2.5
  • Breadth 2.8
  • Evidence 2.7
  • Speed 3.2
  • Durability 2.0
  • Bioindividuality 3.0
Downside
  • Safety Risk 2.0
  • Side Effects 3.0
  • Cost 3.6
  • Effort 3.8
  • Opportunity Cost 3.2
  • Dependency 2.0
  • Reversibility 1.8
Best at:
  • Energy 3.0
  • Longevity 3.0
  • Metabolic Health 2.8
  • Mitochondrial 2.8

The coenzyme itself, given by clinic IV. BioHarmony 5.0, neutral.

Read full BioHarmony report →

Head-to-Head Verdict

Use CaseWinnerRationale
Metabolic HealthNMN (Nicotinamide Mononucleotide)NMN takes this one. Subratings run 6.5 for NMN, 5.0 for NR and 2.8 for direct NAD+, and NMN is the only route with a positive clamp-measured human result behind it. NR's own anchor, Martens 2018, found no insulin sensitivity improvement. Direct NAD+ has no metabolic endpoint measured at all.
Blood SugarNMN (Nicotinamide Mononucleotide)NMN, and the gap is real: 5.0 against NR's 3.0 and 2.4 for direct NAD+. Yoshino 2021 found a 25% improvement in muscle insulin sensitivity in 25 prediabetic postmenopausal women at 250 mg a day for 10 weeks. Dollerup 2018 was explicitly null for NR at 2,000 mg a day. Read the caveat below, because the meta-analyses temper this.
CardiovascularNR (Nicotinamide Riboside)NR wins on a walking-distance endpoint nobody else has. NR 5.0, NMN 4.0, direct NAD+ 2.2. McDermott 2024 (NICE) improved 6-minute walk distance by 17.6 m in peripheral artery disease, and Conze 2019 found directional blood-pressure and arterial-stiffness signals. NMN's best cardiovascular data is a small diastolic signal in Zhang 2026 plus mouse vascular work.
NeuroprotectionNR (Nicotinamide Riboside)NR, on the strength of getting into the brain. NR 5.0, NMN 3.5, direct NAD+ 2.4. NADPARK (Brakedal 2022) raised brain NAD measures and produced early Parkinson's signals, and Nanga 2024 measured a roughly 17% rise in cerebral NAD+ four hours after 900 mg. NMN's neuroprotection case is still preclinical.
EnergyNMN (Nicotinamide Mononucleotide)NMN, narrowly, and none of the three delivers what the marketing implies. NMN 5.5, NR 4.5, direct NAD+ 3.0. NMN is the only one with functional human signals: Wang 2024 pooled gait-speed and ALT improvements across 9 studies. NR's own report says most healthy adults notice nothing. The IV energy lift is drip-feel, measured by nobody.
Cognition FocusTieCall it a tie, because all three failed. NMN and NR both sit at 3.0 and direct NAD+ at 2.6. Wu 2025 raised NAD+ 2.6 to 3.1-fold in long-COVID and cognition still did not beat placebo. Orr 2024 found the same in mild cognitive impairment. There is no completed human NMN cognition RCT and no human cognition trial for direct NAD+.
MemoryTieNobody earns this row. NMN 1.0, NR 1.0, direct NAD+ 2.2. The 2.2 looks like a win and is not one: it is a mechanism score with zero human trials behind it. NR at least tested the question, and Orr 2024 found no cognitive improvement in mild cognitive impairment despite blood NAD+ rising 2.6-fold. Buy a route for another reason.
Telomere DNATieTie, and all three are scoring on mechanism alone. NMN 3.0, NR 2.5, direct NAD+ 2.4. PARP enzymes consume NAD+ during DNA repair, per Fouquerel 2014, which is a real biochemical dependency. No route has a human telomere or DNA-damage endpoint trial. Anyone selling you DNA repair is selling you a pathway diagram.

Cost Comparison

InterventionMonthly CostNotes
NMN$40 to $100Extracted retail pricing, last priced 2026-09-07, at the 500 mg a day oral protocol with a third-party-tested product. Premium liposomal and sublingual forms run above $120 a month with no head-to-head human trial showing they work better. Purity and label-claim variance is the real spend here, so third-party testing is the practical gate, not the format.
NR$40 to $50Extracted retail pricing, last priced 2026-09-07, for Tru Niagen at 300 mg a day, the top of the 250 to 300 mg protocol. Push to 600 mg a day and it runs $70 to $100. The ChromaDex-controlled supply chain is why quality is predictable and why generic price collapse has not happened.
NAD+ (direct IV)$300 to $1,600ESTIMATE, priced 2026-09-07, clinic session channel. US clinics charge roughly $300 to $800 for a 500 mg NAD+ IV. The monthly range assumes one session at the low end and two at the high end. This is a clinic-fee estimate, not a measured price, and it does not include the repeat sessions any sustained effect would require.
The differenceSix to sixteen times more for the IVNR at $50 against a single $300 infusion is a six-fold gap. NMN at $100 against $1,600 for two sessions is sixteen-fold. Same stated goal, and the expensive route is the one with the thinnest human evidence.NR is the cheapest defensible way to raise NAD+ and NMN costs a little more for a better metabolic case. If the infusion price is what makes it feel serious, that is the wrong reason to spend it.

When to Switch

Judge each route on its own clock. NR shows a first change within about 4 hours, full effect around week 6, and an 8-week assessment window. NMN takes about 14 days for a first change, full effect around week 10, and a 12-week window. Direct NAD+ claims a next-day change on a 4-week window, but what changes is the drip experience, not a measured outcome.

Move from NR to NMN when the target is blood sugar or metabolic health and a full 8-week NR window produced nothing on fasting glucose, fasting insulin or HbA1c: NMN's 6.5 metabolic subrating and the Yoshino 2021 clamp result are the reason, and you owe the new route a full 12 weeks. Move from NMN to NR when the target is vascular or neurologic, especially walking distance in peripheral artery disease or a Parkinson's conversation with a neurologist, or when price is the binding constraint. Do not switch from either oral precursor to a NAD+ IV expecting the same effect faster, because the precursors hold the human data and direct NAD+ does not. Going the other way, from IV drips to an oral precursor, is the one switch this comparison recommends without conditions.

Running both precursors is redundant rather than additive: they feed the same salvage pathway, so stack only if you accept paying twice to fill one pool.

Who Should Pick What?

Prediabetic or insulin-resistant adult over 40 tracking fasting insulin and HbA1c

NMN (Nicotinamide Mononucleotide)

Metabolic-health subrating 6.5 against NR's 5.0, and Yoshino 2021 is the one clamp-measured positive result across all three routes. Set a 12-week window, track fasting insulin, HbA1c and blood pressure, and stop if nothing moves.

Older adult with peripheral artery disease and walking limitation

NR (Nicotinamide Riboside)

NICE (McDermott 2024) improved 6-minute walk distance by 17.6 m against placebo under a prespecified criterion. That is the single most concrete functional endpoint any of these three routes has produced. Bring it to your clinician rather than self-starting.

Parkinson's patient discussing an adjunct with a neurologist

NR (Nicotinamide Riboside)

NADPARK (Brakedal 2022) raised brain NAD measures and produced early signals in 30 patients, and NR-SAFE (Berven 2023) tolerated 3,000 mg a day for 4 weeks with methyl-pool monitoring. Neuroprotection subrating 5.0 against NMN's 3.5. Never change Parkinson's treatment without the neurologist.

Healthy 30-year-old chasing energy, focus or a memory edge

Tie

Neither, and not the IV either. Memory scores 1.0, 1.0 and 2.2. Cognition scores 3.0, 3.0 and 2.6. Wu 2025 tripled NAD+ and changed nothing measurable. Spend the $50 a month on training volume, sleep regularity and protein first.

Booked for a $600 NAD+ IV because a clinic said it reverses aging

NR (Nicotinamide Riboside)

Cancel it and buy a precursor. Direct NAD+ has one human study, Grant 2019, and it tracked breakdown and urinary loss rather than any benefit. NR at $40 to $50 a month raised whole-blood NAD+ 142% at 1,000 mg a day in Conze 2019. Twelve months of NR costs less than one infusion.

Active cancer, PARP-inhibitor therapy, pregnancy or breastfeeding

Tie

None of the three. Active malignancy and pregnancy appear on all three contraindication lists. NMN adds PARP-inhibitor therapy specifically, because NAD+ supports both DNA repair and tumor-cell metabolism. Human risk is unproven in either direction, which is exactly why this is not the place to experiment.

Research Highlights

  1. Mechanism Difference

    All three routes fill the same pool, so treat them as redundant rather than complementary. NMN is converted by NMNAT enzymes into NAD+. NR enters the NRK1 and NRK2 route, becomes NMN, then feeds the same salvage pathway.Direct NAD+ skips the precursor step entirely, but that is the problem rather than the shortcut. Extracellular NAD+ triggers a rebuilding response inside the cell, per Buonvicino 2021, so even an infusion likely arrives as fragments your cells reassemble.

  2. Bioavailability

    Oral bioavailability is the whole argument. NAD+ is a large doubly charged dinucleotide of about 663 daltons that degrades in the gut largely to nicotinamide before absorption, which is exactly why the validated supplement route sells small precursors instead.NR is orally bioavailable and raised whole-blood NAD+ 22%, 51% and 142% at 100, 300 and 1,000 mg a day, per Conze 2019. NMN's own intestinal transporter claim is contested: Grozio 2019 proposed Slc12a8 and Schmidt and Brenner 2019 disputed it.

  3. Safety Comparison

    No route here carries a serious safety signal, and the contraindication lists overlap heavily. Pregnancy, breastfeeding and active malignancy appear on all three. NMN adds PARP-inhibitor therapy. NR adds severe kidney disease and Parkinson's treatment changes.The difference is route, not molecule. NMN and NR score 1.5 and 1.4 on safety risk with mild gastrointestinal complaints as the usual problem. Direct NAD+ scores 2.0 on safety and 3.0 on side effects, driven by infusion-rate flushing, nausea and chest tightness.

  4. Cost Comparison

    NR is the cheapest at $40 to $50 a month for Tru Niagen at 300 mg a day. NMN runs $40 to $100 a month at 500 mg a day, with liposomal versions above $120 and no head-to-head trial behind them. Both figures are extracted retail prices from 2026-09-07.Direct NAD+ is an ESTIMATE: US clinics charge roughly $300 to $800 for a 500 mg IV, so $300 to $1,600 a month at one or two sessions. Same stated goal, six to sixteen times the price, thinnest evidence.

  5. Editorial Verdict

    NMN at 6.3 and NR at 6.1 are a coin flip on score, so choose by endpoint. NMN owns blood sugar and metabolic health on Yoshino 2021, a 25% muscle insulin sensitivity gain in 25 prediabetic postmenopausal women.NR owns cardiovascular and neuroprotection on McDermott 2024 and NADPARK. Direct NAD+ at 5.0 wins no use case in this comparison. Across all three, NAD+ rises far more reliably than any outcome does, so set a window and a stop rule before you start.

Frequently Asked Questions

Is NMN or NR better?
Depends on your target. NMN scores 6.3 and NR 6.1, which is a tie in practice. NMN wins metabolic health (6.5 against 5.0) and blood sugar (5.0 against 3.0) on Yoshino 2021. NR wins cardiovascular (5.0 against 4.0) and neuroprotection (5.0 against 3.5) on the NICE walking trial and NADPARK. NR is also slightly cheaper.
Is a NAD+ IV worth it?
Not on the evidence. Direct NAD+ scores 5.0 and wins no use case in this comparison. The entire human file is one pharmacokinetic study, Grant 2019, which tracked where infused NAD+ went and how fast it broke down, never whether anyone improved. A clinic session is an ESTIMATED $300 to $800. A year of NR costs less than one infusion.
Why can't you just swallow NAD+?
Because it does not survive the trip. NAD+ is a large doubly charged dinucleotide of about 663 daltons and it degrades in the gut largely to nicotinamide before absorption. That is the whole reason the supplement market sells NMN and NR instead: small precursors your cells convert once they are inside.
Does taking NMN or NR actually make you feel different?
Usually not, and both reports say so. NAD+ rises far more reliably than symptoms do. NR's own energy rationale notes most healthy adults report no obvious subjective effect despite biochemical elevation. NMN's functional signals are gait speed and ALT in Wang 2024, which you measure rather than feel. Track a number, not a mood.
Can I take NMN and NR together?
You can, but it is redundant rather than additive. NR is converted to NMN before it becomes NAD+, so both routes feed the same salvage pathway and the same pool. Stacking them means paying twice to fill one tank. If you want to cover more ground, spend the second budget on training volume and sleep, which raise NAD+ for free.
How long should I run a trial before deciding?
Give NR 8 weeks and NMN 12. NR shows a first change within about 4 hours and full effect around week 6. NMN takes about 14 days for a first change and reaches full effect around week 10. Judge at the end of the window against a marker you chose in advance, then stop if nothing moved.
Do any of these help memory or mood?
No. Memory subratings are 1.0 for NMN, 1.0 for NR and 2.2 for direct NAD+, and mood is the same shape. Orr 2024 raised blood NAD+ 2.6-fold in mild cognitive impairment with no cognitive improvement. Wu 2025 found no significant anxiety or depression benefit in long-COVID. The 2.2 on direct NAD+ is mechanism scoring, not evidence.
Who should avoid all three?
Anyone pregnant, breastfeeding or with active malignancy. Those appear on all three contraindication lists. NMN adds PARP-inhibitor therapy. NR adds severe kidney disease and Parkinson's treatment changes.Direct NAD+ adds severe cardiovascular disease, because infusion-rate flushing and chest tightness are the known reactions.

Evidence Sources

Glossary

Quick reference for the medical and technical terms used in this comparison.

NAD+ Nicotinamide Adenine Dinucleotide
The central redox coenzyme of energy metabolism, and a substrate consumed by sirtuins, PARPs and CD38. Tissue levels fall with age, which is the reason all three routes exist.
NMN Nicotinamide Mononucleotide
An oral NAD+ precursor one enzymatic step from NAD+. NMNAT enzymes make the conversion.
NR Nicotinamide Riboside
An oral vitamin B3 derivative. NRK1 and NRK2 kinases convert it to NMN first, so it is two steps from NAD+.
NMNAT Nicotinamide Mononucleotide Adenylyltransferase
The enzyme family that converts NMN into NAD+. The last step of both oral routes.
Salvage pathway NAD+ Salvage Pathway
The route cells use to rebuild NAD+ from smaller fragments. Both precursors feed it, and it is also the likely fate of much infused NAD+.
SLC25A51 Mitochondrial NAD+ Transporter
The carrier that loads the mitochondrial NAD+ pool. It sits on the mitochondrion rather than the cell surface, which is the core reason intact uptake of infused NAD+ is contested.
Slc12a8 Proposed Intestinal NMN Transporter
A contested transporter. Grozio 2019 proposed it carries NMN intact across the gut wall; Schmidt and Brenner 2019 disputed the claim.
PARP Poly(ADP-ribose) Polymerase
A DNA-repair enzyme family that consumes NAD+ while it works. The mechanistic basis for every DNA-repair claim in this comparison, and the reason PARP-inhibitor therapy is an NMN contraindication.
CD38 Cyclic ADP Ribose Hydrolase
An NAD-consuming enzyme that rises with age and inflammation. It is why a one-time bolus does not durably change the pool.
PK study Pharmacokinetic Study
A study of where a substance goes and how fast it breaks down, rather than whether it helps. The single human direct-NAD+ study is this kind.
Nick Urban

Health Optimization Researcher & CHEK Holistic Lifestyle Coach Level 2

I have spent over a decade testing longevity and metabolic supplements on myself and screening them for clients and podcast guests

Reviewed Sep 7, 2026 · next review Dec 6, 2026

Find which one fits your biology

Take the BioHarmony Quiz